Management of conjunctival malignant melanoma: a review and update

References

• Isager P, Engholm G, Overgaard J, et al. Uveal and conjunctival malignant melanoma in Denmark 1943–97: observed and relative survival of patients followed through 2002. Ophthalmic Epidemiol 2006;13(2):85-96
   PubMed Web of Science ®Google Scholar
• Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83(8):1664-78
   PubMed Web of Science ®Google Scholar
• Seregard S. Conjunctival melanoma. Surv Ophthalmol 1998;42(4):321-50
   PubMed Web of Science ®Google Scholar
• Triay E, Bergman L, Nilsson B, et al. Time trends in the incidence of conjunctival melanoma in Sweden. Br J Ophthalmol 2009;93(11):1524-8
   PubMed Web of Science ®Google Scholar
• Yu GP, Hu DN, McCormick S, et al. Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol 2003;135(6):800-6
   PubMed Web of Science ®Google Scholar
• Tuomaala S, Eskelin S, Tarkkanen A, et al. Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites. Invest Ophthalmol Vis Sci 2002;43(11):3399-408
   PubMed Web of Science ®Google Scholar
• Isager P, Østerlind A, Engholm G, et al. Uveal and conjunctival malignant melanoma in Denmark, 1943–97: incidence and validation study. Ophthalmic Epidemiol 2005;12(4):223-32
   PubMed Web of Science ®Google Scholar
• Missotten GS, Keijser S, De Keizer R, et al. Conjunctival melanoma in The Netherlands: a nationwide study. Invest Ophthalmol Vis Sci 2005;46(1):75-82
   PubMed Web of Science ®Google Scholar
• Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005;41(14):2040-59
   PubMed Web of Science ®Google Scholar
• Thomas NE, Edmiston SN, Alexander A, et al. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomark Prev 2007;16(5):991-7
   PubMed Web of Science ®Google Scholar
• Balato N, Gaudiello F, Balato A, et al. Sun habits in the children of Southern Italy. J Am Acad Dermatol 2007;57(5):883-7
   Google Scholar
• Cooper C, Sorrell J, Gerami P. Update in molecular diagnostics in melanocytic neoplasms. Adv Anat Pathol 2012;19(6):410-16
   Google Scholar
• Paszkowska-Szczur K, Scott RJ, Serrano-Fernandez P, et al. Xeroderma pigmentosum genes and melanoma risk. Int J Cancer J 2013;133(5):1094-100
   Google Scholar
• Braam KI, Overbeek A, Kaspers GJL, et al. Malignant melanoma as second malignant neoplasm in long-term childhood cancer survivors: a systematic review. Pediatr Blood Cancer 2012;58(5):665-74
   Google Scholar
• Hurst EA, Harbour JW, Cornelius LA. Ocular melanoma: a review and the relationship to cutaneous melanoma. Arch Dermatol 2003;139(8):1067-73
   PubMedGoogle Scholar
• Hemminki K, Chen B. Familial risks for eye melanoma and retinoblastoma: results from the Swedish Family-Cancer Database. Melanoma Res 2006;16(2):191-5
   PubMed Web of Science ®Google Scholar
• Hu DN, Yu G, McCormick SA, et al. Population-based incidence of conjunctival melanoma in various races and ethnic groups and comparison with other melanomas. Am J Ophthalmol 2008;145(3):418-23
   PubMed Web of Science ®Google Scholar
• McLaughlin CC, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the U.S. Cancer 2005;103(5):1000-7
   PubMed Web of Science ®Google Scholar
• Shields CL, Shields JA, Gündüz K, et al. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol 2000;118(11):1497
   PubMedGoogle Scholar
• Shields CL, Markowitz JS, Belinsky I, et al. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology 2011;118(2):389-95. e2
   PubMed Web of Science ®Google Scholar
• Shields JA, Shields CL, Mashayekhi A, et al. Primary acquired melanosis of the conjunctiva: experience with 311 eyes. Trans Am Ophthalmol Soc 2007;105:61
   PubMedGoogle Scholar
• Shields CL, Kaliki S, Al-Dahmash SA, et al. American Joint Committee on Cancer (AJCC) clinical classification predicts conjunctival melanoma outcomes. Ophthal Plast Reconstr Surg. 2012;28(5):313-23
   Google Scholar
• Shields JA, Shields CL, Mashayekhi A, et al. Primary acquired melanosis of the conjunctiva: risks for progression to melanoma in 311 eyes: the 2006 Lorenz E. Zimmerman Lecture. Ophthalmology 2008;115(3):511-19. e2
   Google Scholar
• Shields CL, Fasiuddin AF, Fasiudden A, et al. Conjunctival nevi: clinical features and natural course in 410 consecutive patients. Arch Ophthalmol 2004;122(2):167-75
   PubMedGoogle Scholar
• Kenawy N, Lake SL, Coupland SE, et al. Conjunctival melanoma and melanocytic intra-epithelial neoplasia. Eye 2012;27(2):142-52
   Google Scholar
• Anastassiou G, Heiligenhaus A, Bechrakis N, et al. Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study. Br J Ophthalmol 2002;86(2):163-7
   PubMed Web of Science ®Google Scholar
• Paridaens AD, Minassian DC, McCartney AC, et al. Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases. Br J Ophthalmol 1994;78(4):252-9
   PubMed Web of Science ®Google Scholar
• Lim M, Tatla T, Hersh D, et al. Patterns of regional head and neck lymph node metastasis in primary conjunctival malignant melanoma. Br J Ophthalmol 2006;90(12):1468-71
   Google Scholar
• Esmaeli B, Wang X, Youssef A, et al. Patterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades. Ophthalmology 2001;108(11):2101-5
   PubMed Web of Science ®Google Scholar
• Brownstein S. Malignant melanoma of the conjunctiva. Cancer Control 2004;11(5):310-16
   PubMedGoogle Scholar
• Damato B, Coupland SE. Management of conjunctival melanoma. Expert Rev Anticancer Ther 2009;9(9):1227-39
   PubMed Web of Science ®Google Scholar
• Kurli M, Finger P. Melanocytic Conjunctival Tumors. Ophthalmol Clin N Am 2005;18(1):15-24
   Google Scholar
• Paridaens AD, McCartney AC, Lavelle RJ, et al. Nasal and orbital recurrence of conjunctival melanoma 21 years after exenteration. Br J Ophthalmol 1992;76(6):369-71
   Google Scholar
• Oellers P, Karp CL. Management of pigmented conjunctival lesions. Ocul Surf 2012;10(4):251-63
   PubMed Web of Science ®Google Scholar
• Jakobiec FA, Folberg R, Iwamoto T. Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva. Ophthalmology 1989;96(2):147-66
   Google Scholar
• Momose M, Ota H, Hayama M. Re-evaluation of melanin bleaching using warm diluted hydrogen peroxide for histopathological analysis: melanin-bleaching. Pathol Int 2011;61(6):345-50
   Google Scholar
• Zembowicz A, Mandal RV, Choopong P. Melanocytic lesions of the conjunctiva. Arch Pathol Lab Med 2010;134(12):1785-92
   Google Scholar
• Henderson E, Margo CE. Iris melanoma. Arch Pathol Lab Med 2008;132(2):268-72
   Google Scholar
• Perez MT, Suster S. Balloon cell change in cellular blue nevus. Am J Dermatopathol 1999;21(2):181-4
   Google Scholar
• Calonje E, Brenn T, Lazar A, et al. Benign melanocytic tumors. In: McKee’s pathology of the skin. Elsevier; Amsterdam, NL, USA: 2011. p. 1277-87
   Google Scholar
• Folberg R, McLean IW, Zimmerman LE. Malignant melanoma of the conjunctiva. Hum Pathol 1985;16(2):136-43
   Google Scholar
• Liesegang TJ, Campbell RJ. Mayo Clinic experience with conjunctival melanomas. Arch Ophthalmol 1980;98(8):1385
   Google Scholar
• Meallet MA, Espana EM, Grueterich M, et al. Amniotic membrane transplantation with conjunctival limbal autograft for total limbal stem cell deficiency. Ophthalmology 2003;110(8):1585-92
   Google Scholar
• Paridaens AD, McCartney AC, Curling OM, et al. Impression cytology of conjunctival melanosis and melanoma. Br J Ophthalmol 1992;76(4):198-201
   Google Scholar
• Keijser S, van Luijk CM, Missotten GS, et al. Predictive value of exfoliative cytology in pigmented conjunctival lesions. Acta Ophthalmol Scand 2006;84(2):188-91
   Google Scholar
• Gelender H, Forster RK. Papanicolaou cytology in the diagnosis and management of external ocular tumors. Arch Ophthalmol 1980;98(5):909-12
   Google Scholar
• Tananuvat N, Lertprasertsuk N, Mahanupap P, et al. Role of impression cytology in diagnosis of ocular surface neoplasia. Cornea 2008;27(3):269-74
   PubMed Web of Science ®Google Scholar
• Barros JN, Lowen MS, Ballalai PL, et al. Predictive index to differentiate invasive squamous cell carcinoma from preinvasive ocular surface lesions by impression cytology. Br J Ophthalmol 2009;93(2):209-14
   Google Scholar
• Häring G, Nölle B, Wiechens B. Ultrasound biomicroscopic imaging in intermediate uveitis. Br J Ophthalmol 1998;82(6):625-9
   PubMed Web of Science ®Google Scholar
• Ho VH, Prager TC, Diwan H, et al. Ultrasound biomicroscopy for estimation of tumor thickness for conjunctival melanoma. J Clin Ultrasound 2007;35(9):533-7
   Google Scholar
• Bianciotto C, Shields CL, Guzman JM, et al. Assessment of anterior segment tumors with ultrasound biomicroscopy versus anterior segment optical coherence tomography in 200 cases. Ophthalmology 2011;118(7):1297-302
   PubMed Web of Science ®Google Scholar
• Silverman RH, Cannata J, Shung KK, et al. 75 MHz ultrasound biomicroscopy of anterior segment of eye. Ultrason Imaging 2006;28(3):179-88
   Google Scholar
• Shousha MA, Karp CL, Canto AP, et al. Diagnosis of Ocular Surface Lesions Using Ultra–High-Resolution Optical Coherence Tomography. Ophthalmology 2013;120(5):883-91
   PubMed Web of Science ®Google Scholar
• Erie JC, McLaren JW, Patel SV. Confocal microscopy in ophthalmology. Am J Ophthalmol 2009;148(5):639-46
   Google Scholar
• Messmer EM, Mackert MJ, Zapp DM, Kampik A. In vivo confocal microscopy of pigmented conjunctival tumors. Graefes Arch Clin Exp Ophthalmol 2006;244(11):1437-45
   Google Scholar
• Wilson JW, Vajzovic L, Robles FE, et al. Imaging microscopic pigment chemistry in conjunctival melanocytic lesions using pump-probe laser microscopy. Invest Ophthalmol Vis Sci 2013;54(10):6867-76
   Google Scholar
• Mudhar HS, Smith K, Talley P, et al. Fluorescence in situ hybridisation (FISH) in histologically challenging conjunctival melanocytic lesions. Br J Ophthalmol 2012;97(1):40-6
   Google Scholar
• Reese AB. Precancerous and cancerous melanosis. Am J Ophthalmol 1966;61(5 Pt 2):1272-7
   Google Scholar
• Paridaens AD, McCartney AC, Minassian DC, et al. Orbital exenteration in 95 cases of primary conjunctival malignant melanoma. Br J Ophthalmol 1994;78(7):520-8
   PubMed Web of Science ®Google Scholar
• Poli T, Mora P, Reichegger V, et al. Surgical management of orbital malignant melanoma: our experience and a report of three cases. Klin Monatsblätter Für Augenheilkd 2007;224(10):794-8
   Google Scholar
• Shields JA, Shields CL, De Potter P. Surgical management of conjunctival tumors. The 1994 Lynn B. McMahan Lecture. Arch Ophthalmol 1997;115(6):808-15
   PubMedGoogle Scholar
• Chen J-Q, Sun M, Sha X, et al. Management of corneo-conjunctival malignant melanoma with “no touch technique” surgical excision and corneoscleral lamellar keratoplasty. Zhonghua Yan Ke Za Zhi 2006;42(1):22-6
   Google Scholar
• Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, et al. Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol 2013;6(7):1230-44
   PubMed Web of Science ®Google Scholar
• Burattini S, Battistelli M, Falcieri E. Morpho-functional features of in-vitro cell death induced by physical agents. Curr Pharm Des 2010;16(12):1376-86
   Google Scholar
• Shields CL, Shields JA, Armstrong T. Management of conjunctival and corneal melanoma with surgical excision, amniotic membrane allograft, and topical chemotherapy. Am J Ophthalmol 2001;132(4):576-8
   Google Scholar
• Paridaens D, Beekhuis H, van den Bosch W, et al. Amniotic membrane transplantation in the management of conjunctival malignant melanoma and primary acquired melanosis with atypia. Br J Ophthalmol 2001;85(6):658-61
   Google Scholar
• Becerra E, Blanco G, Saornil M, et al. Hughes technique, amniotic membrane allograft, and topical chemotherapy in conjunctival melanoma with eyelid involvement. Ophthal Plast Reconstr Surg 2005;21(3):235-6
   Google Scholar
• Liu J, Sheha H, Fu Y, et al. Update on amniotic membrane transplantation. Expert Rev Ophthalmol 2010;5(5):645-61
   PubMedGoogle Scholar
• Meller D, Pauklin M, Thomasen H, et al. Amniotic membrane transplantation in the human eye. Dtsch Ärztebl Int 2011;108(14):243-8
   PubMed Web of Science ®Google Scholar
• Dua HS, Azuara-Blanco A. Amniotic membrane transplantation. Br J Ophthalmol 1999;83(6):748-52
   PubMed Web of Science ®Google Scholar
• Biswas MC, Dutta S, Nath U, et al. Malignant melanoma of conjunctiva – a case report. J Indian Med Assoc 2004;102(12):730-64
   Google Scholar
• Jakobiec FA, Rini FJ, Fraunfelder FT, et al. Cryotherapy for conjunctival primary acquired melanosis and malignant melanoma. Experience with 62 cases. Ophthalmology 1988;95(8):1058-70
   Google Scholar
• Hodson K, Karp CL. Excision of circumsribed conjunctival melanoma with amniotic membrane transplantation. Tech Ophthalmol 2011;9:5-9
   Google Scholar
• Fraunfelder FW. Liquid nitrogen cryotherapy for surface eye disease (an AOS thesis). Trans Am Ophthalmol Soc 2008;106:301
   Google Scholar
• Giaconi JA, Karp CL. Current treatment options for conjunctival and corneal intraepithelial neoplasia. Ocul Surf 2003;1(2):66-73
   Google Scholar
• Tucker SM, Hurwitz JJ, Pavlin CJ, et al. Scleral melt after cryotherapy for conjunctival melanoma. Ophthalmology 1993;100(4):574-7
   Google Scholar
• Ditta LC, Shildkrot Y, Wilson MW. Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences. Ophthalmology 2011;118(9):1754-9
   PubMed Web of Science ®Google Scholar
• Kurli M, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years’ experience. Graefes Arch Clin Exp Ophthalmol 2005;243(11):1108-14
   PubMed Web of Science ®Google Scholar
• Finger PT, Czechonska G, Liarikos S. Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia. Br J Ophthalmol 1998;82(5):476-9
   Google Scholar
• Demirci H, McCormick SA, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations. Arch Ophthalmol 2000;118(7):885-91
   Google Scholar
• Fernandes BF, Nikolitch K, Coates J, et al. Local chemotherapeutic agents for the treatment of ocular malignancies. Surv Ophthalmol 2014;59(1):97-114
   PubMed Web of Science ®Google Scholar
• Fujioka M, Sakamoto M, Azumi A, et al. A case of conjunctival malignant melanoma treated with subconjunctival injection of interferon beta--efficacy and side effects. Nippon Ganka Gakkai Zasshi 2006;110(1):51-7
   Google Scholar
• Herold TR, Hintschich C. Interferon α for the treatment of melanocytic conjunctival lesions. Graefes Arch Clin Exp Ophthalmol 2009;248(1):111-15
   Google Scholar
• Finger PT, Sedeek RW, Chin KJ. Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex. Am J Ophthalmol 2008;145(1):124-9
   PubMed Web of Science ®Google Scholar
• Verweij J, Pinedo HM. Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs 1990;1(1):5-13
   PubMedGoogle Scholar
• Abraham LM, Selva D, Casson R, et al. Mitomycin: clinical applications in ophthalmic practice. Drugs 2006;66(3):321-40
   PubMed Web of Science ®Google Scholar
• Chalasani R, Giblin M, Conway RM. Role of topical chemotherapy for primary acquired melanosis and malignant melanoma of the conjunctiva and cornea: review of the evidence and recommendations for treatment. Clin Experiment Ophthalmol 2006;34(7):708-14
   PubMed Web of Science ®Google Scholar
• Kemp EG, Harnett AN, Chatterjee S. Preoperative topical and intraoperative local mitomycin C adjuvant therapy in the management of ocular surface neoplasias. Br J Ophthalmol 2002;86(1):31-4
   PubMed Web of Science ®Google Scholar
• Rodríguez-Ares T, Touriño R, De Rojas V, et al. Topical mitomycin C in the treatment of pigmented conjunctival lesions. Cornea 2003;22(2):114-17
   Google Scholar
• Pe’er J, Frucht-Pery J. The treatment of primary acquired melanosis (PAM) with atypia by topical mitomycin C. Am J Ophthalmol 2005;139(2):229-34
   Google Scholar
• Finger PT, Milner MS, McCormick SA. Topical chemotherapy for conjunctival melanoma. Br J Ophthalmol 1993;77(11):751-3
   Google Scholar
• Russell HC, Chadha V, Lockington D, et al. Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol 2010;94(10):1316-21
   PubMed Web of Science ®Google Scholar
• Gupta A, Muecke J. Treatment of ocular surface squamous neoplasia with Mitomycin C. Br J Ophthalmol 2010;94(5):555-8
   PubMed Web of Science ®Google Scholar
• Lichtinger A, Pe’er J, Frucht-Pery J, et al. limbal stem cell deficiency after topical mitomycin C therapy for primary acquired melanosis with atypia. Ophthalmology 2010;117(3):431-7
   PubMed Web of Science ®Google Scholar
• Khong JJ, Muecke J. Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol 2006;90(7):819-22
   PubMed Web of Science ®Google Scholar
• Shields CL, Naseripour M, Shields JA. Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma. Am J Ophthalmol 2002;133(5):601-6
   PubMed Web of Science ®Google Scholar
• Daniell M, Maini R, Tole D. Use of mitomycin C in the treatment of corneal conjunctival intraepithelial neoplasia. Clin Experiment Ophthalmol 2002;30(2):94-8
   Google Scholar
• Baron S, Tyring SK, Fleischmann WR Jr, et al. The interferons. mechanisms of action and clinical applications. JAMA 1991;266(10):1375-83
   PubMed Web of Science ®Google Scholar
• Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007;89(6-7):884-93
   PubMed Web of Science ®Google Scholar
• Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006;24(19):3164-71
   PubMed Web of Science ®Google Scholar
• Karp CL, Galor A, Chhabra S, et al. Subconjunctival/perilesional recombinant interferon α2b for ocular surface squamous neoplasia: a 10-year review. Ophthalmology 2010;117(12):2241-6
   PubMed Web of Science ®Google Scholar
• Nanji AA, Sayyad FE, Karp CL. Topical chemotherapy for ocular surface squamous neoplasia. Curr Opin Ophthalmol 2013;24(4):336-42
   PubMed Web of Science ®Google Scholar
• Vann RR, Karp CL. Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia. Ophthalmology 1999;106(1):91-7
   PubMed Web of Science ®Google Scholar
• Lommatzsch PK, Lommatzsch RE, Kirsch I, et al. Therapeutic outcome of patients suffering from malignant melanomas of the conjunctiva. Br J Ophthalmol 1990;74(10):615-19
   Google Scholar
• Stannard C, Sauerwein W, Maree G, et al. Radiotherapy for ocular tumours. Eye Lond 2013;27(2):119-27
   PubMed Web of Science ®Google Scholar
• Shields JA, Shields CL, Freire JE, et al. Plaque radiotherapy for selected orbital malignancies: preliminary observations: The 2002 Montgomery Lecture, Part 2. Ophthal Plast Reconstr Surg 2003;19(2):91-5
   Google Scholar
• Cohen VML, Papastefanou VP, Liu S, et al. The use of strontium-90 beta radiotherapy as adjuvant treatment for conjunctival melanoma. J Oncol 2013;2013:349162
   Google Scholar
• Zehetmayer M, Menapace R, Kulnig W. Combined local excision and brachytherapy with ruthenium-106 in the treatment of epibulbar malignancies. Ophthalmologica 1993;207(3):133-9
   PubMedGoogle Scholar
• Krause L, Mladenova A, Bechrakis NE, et al. Treatment modalities for conjunctival melanoma. Klin Monatsblätter Für Augenheilkd 2009;226(12):1012-16
   Google Scholar
• Karim R, Conway RM. Conservative resection and adjuvant plaque brachytherapy for early-stage conjunctival melanoma. Clin Experiment Ophthalmol 2011;39(4):293-8
   PubMed Web of Science ®Google Scholar
• Missotten G, De Keizer R, Spileers W, Blank L. Strontium brachytherapy in conjunctival melanoma. Acta Ophthalmol (Copenh) 2011;89:s248
   Google Scholar
• Krause L, Ritter C, Wachtlin J, et al. Recurrence rate following adjuvant strontium-90 brachytherapy after excision of conjunctival melanoma. Klin Monbl Augenheilkd 2008;225(7):649-52
   Google Scholar
• Walsh-Conway N, Conway RM. Plaque brachytherapy for the management of ocular surface malignancies with corneoscleral invasion. Clin Experiment Ophthalmol 2009;37(6):577-83
   PubMed Web of Science ®Google Scholar
• Kaliki S, Shields CL, Rojanaporn D, et al. Scleral necrosis after plaque radiotherapy of uveal melanoma: a Case-Control Study. Ophthalmology 2013;120(5):1004-11
   PubMed Web of Science ®Google Scholar
• Wuestemeyer H, Sauerwein W, Meller D, et al. Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma. Graefes Arch Clin Exp Ophthalmol 2005;244(4):438-46
   Google Scholar
• Hsu A, Frank SJ, Ballo MT, et al. Postoperative adjuvant external-beam radiation therapy for cancers of the eyelid and conjunctiva. Ophthal Plast Reconstr Surg 2008;24(6):444-9
   PubMed Web of Science ®Google Scholar
• Norregaard JC, Gerner N, Jensen OA, et al. Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population. Graefes Arch Clin Exp Ophthalmol 1996;234(9):569-72
   PubMed Web of Science ®Google Scholar
• Stephens LC, Schultheiss TE, Price RE, et al. Radiation apoptosis of serous acinar cells of salivary and lacrimal glands. Cancer 1991;67(6):1539-43
   Google Scholar
• Durkin SR, Roos D, Higgs B, et al. Ophthalmic and adnexal complications of radiotherapy. Acta Ophthalmol Scand 2007;85(3):240-50
   PubMedGoogle Scholar
• Garrott H, O’Day J. Optic neuropathy secondary to radiotherapy for nasal melanoma. Clin Experiment Ophthalmol 2004;32(3):330-3
   Google Scholar
• Macfaul PA, Bedford MA. Ocular complications after therapeutic irradiation. Br J Ophthalmol 1970;54(4):237-47
   PubMed Web of Science ®Google Scholar
• Jakobiec FA, Brownstein S, Wilkinson RD, et al. Combined surgery and cryotherapy for diffuse malignant melanoma of the conjunctiva. Arch Ophthalmol 1980;98(8):1390-6
   Google Scholar
• Jakobiec FA, Brownstein S, Wilkinson RD, et al. Adjuvant cryotherapy for focal nodular melanoma of the conjunctiva. Arch Ophthalmol 1982;100(1):115-18
   Google Scholar
• Cohen VML, Tsimpida M, Hungerford JL, et al. Prospective study of sentinel lymph node biopsy for conjunctival melanoma. Br J Ophthalmol 2013;97(12):1525-9
   PubMed Web of Science ®Google Scholar
• Esmaeli B, De Martelaere S, Ozkan Y, et al. Surgical specimen handling for conjunctival melanoma: implications for tumor thickness determination and sentinel lymph node biopsy. Ophthal Plast Reconstr Surg 2006;22(3):238-9
   Google Scholar
• Pfeiffer ML, Savar A, Esmaeli B. Sentinel lymph node biopsy for eyelid and conjunctival tumors: what have we learned in the past decade? Ophthal Plast Reconstr Surg 2013;29(1):57-62
   Google Scholar
• Tuomaala S, Kivelä T. Metastatic pattern and survival in disseminated conjunctival melanoma: implications for sentinel lymph node biopsy. Ophthalmology 2004;111(4):816-21
   Google Scholar
• Savar A, Ross MI, Prieto VG, et al. Sentinel lymph node biopsy for ocular adnexal melanoma: experience in 30 patients. Ophthalmology 2009;116(11):2217-23
   Google Scholar
• Esmaeli B, Reifler D, Prieto VG, et al. Conjunctival melanoma with a positive sentinel lymph node. Arch Ophthalmol 2003;121(12):1779-83
   Google Scholar
• Morton DL, Cochran AJ, Thompson JF. The rationale for sentinel-node biopsy in primary melanoma. Nat Clin Pract Oncol 2008;5(9):510-11
   Google Scholar
• Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355(13):1307-17
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27(36):6199-206
   PubMed Web of Science ®Google Scholar
• Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014;370(7):599-609
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE. Clinical value of the sentinel-node biopsy in primary cutaneous melanoma. N Engl J Med 2014;370(7):663-4
   PubMed Web of Science ®Google Scholar
• Baroody M, Holds JB, Kokoska MS, et al. Conjunctival melanoma metastasis diagnosed by sentinel lymph node biopsy. Am J Ophthalmol 2004;137(6):1147-9
   Google Scholar
• Motomura H, Sakamoto M, Maruyama Y, et al. Sentinel lymph node biopsy in conjunctival malignant melanoma at the lacrimal caruncle: a case report. Osaka City Med J 2010;56(1):5-10
   Google Scholar
• Schwarz KA, Davison SP, Crane AE. Sentinel lymph node biopsy in the setting of conjunctival melanoma. Plast Reconstr Surg 2008;121(4):212e-3e
   Google Scholar
• Nijhawan N, Ross MI, Diba R, et al. Experience with sentinel lymph node biopsy for eyelid and conjunctival malignancies at a Cancer Center: ophthal Plast Reconstr Surg. 2004;20(4):291-5
   Google Scholar
• Werschnik C, Lommatzsch PK. Long-term follow-up of patients with conjunctival melanoma. Am J Clin Oncol 2002;25(3):248-55
   PubMed Web of Science ®Google Scholar
• Sentinel lymph node (SLN) biopsy for conjunctival/eyelid melanoma. Available from: http://clinicaltrials.gov/show/NCT00386906
   Google Scholar
• Shildkrot Y, Wilson MW. Conjunctival melanoma: pitfalls and dilemmas in management. Curr Opin Ophthalmol 2010;21(5):380-6
   Google Scholar
• Kurli M, Chin K, Finger PT. Whole-body 18 FDG PET/CT imaging for lymph node and metastatic staging of conjunctival melanoma. Br J Ophthalmol 2008;92(4):479-82
   Google Scholar
• Damian A, Gaudiano J, Engler H, et al. (18)F-FDG PET-CT for staging of conjunctival melanoma. World J Nucl Med 2013;12(1):45-7
   Google Scholar
• Damato B, Coupland S. An audit of conjunctival melanoma treatment in Liverpool. Eye Lond 2009;23:801-9
   PubMed Web of Science ®Google Scholar
• Esmaeli B, Roberts D, Ross M, et al. Histologic features of conjunctival melanoma predictive of metastasis and death (An American Ophthalmological Thesis). Trans Am Ophthalmol Soc 2012;110:64-73
   PubMedGoogle Scholar
• Cohen VM, Ahmadi-lari S, Hungerford JL. Gastric metastases from conjunctival melanoma. Melanoma Res 2007;17(4):255-6
   PubMed Web of Science ®Google Scholar
• Gökme SH, Ardiç F. Malignant conjunctival tumors invading the orbit. Ophthalmologica 2008;222(5):338-43
   Google Scholar
• Missotten GS, Gambrelle J, de Wolff-Rouendaal D, de Keizer RJW. Epistaxis or epiphora as a sign for extension of a conjunctival melanoma. A series of six patients with nasolacrimal recurrence. Br J Ophthalmol 2010;94(10):1328-31
   Google Scholar
• Edge SB, Byrd DR, Compton CC, et al. Malignant melanoma of the conjunctiva. In: AJCC cancer staging manual. Springer; New York, NY, USA: p. 541–48 2010
   Google Scholar
• Spendlove HE, Damato BE, Humphreys J, et al. BRAF mutations are detectable in conjunctival but not uveal melanomas. Melanoma Res 2004;14(6):449-52
   PubMed Web of Science ®Google Scholar
• Griewank KG, Westekemper H, Murali R, et al. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res 2013;19(12):3143-52
   PubMed Web of Science ®Google Scholar
• Griewank KG, Murali R, Schilling B, et al. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer 2013;109(2):497-501
   PubMed Web of Science ®Google Scholar
• Lake SL, Jmor F, Dopierala J, et al. Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes. Invest Ophthalmol Vis Sci 2011;52(8):5598-604
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364(26):2517-26
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366(8):707-14
   PubMed Web of Science ®Google Scholar
• Box NF, Vukmer TO, Terzian T. Targeting p53 in melanoma. Pigment Cell Melanoma Res 2014;27(1):8-10
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54
   PubMed Web of Science ®Google Scholar
• Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008;105(8):3041-6
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507-16
   PubMed Web of Science ®Google Scholar
• Torkamani A, Schork NJ. Prediction of cancer driver mutations in protein kinases. Cancer Res 2008;68(6):1675-82
   Google Scholar
• Gear H, Williams H, Kemp E, Roberts F. BRAF Mutations in conjunctival melanoma. Invest Ophthalmol Vis Sci 2004;45(8):2484-8
   PubMed Web of Science ®Google Scholar
• Goldenberg-Cohen N, Cohen Y, Rosenbaum E, et al. T1799A BRAF Mutations in Conjunctival Melanocytic Lesions. Invest Ophthalmol Vis Sci 2005;46(9):3027-30
   Google Scholar
• Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14(21):6821-8
   PubMed Web of Science ®Google Scholar
• THE IPI - trial in advanced melanoma: melanoma patients with advanced disease (DeCOG). Available from: http://clinicaltrials.gov/show/NCT01355120
   Google Scholar
• Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-Cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010;70(13):5213-19
   PubMed Web of Science ®Google Scholar
• Wallander ML, Layfield LJ, Emerson LL, et al. KIT mutations in ocular melanoma: frequency and anatomic distribution. Mod Pathol 2011;24(8):1031-5
   Google Scholar
• Alessandrini L, Parrozzani R, Bertorelle R, et al. C-Kit SCF receptor (CD117) expression and KIT gene mutation in conjunctival pigmented lesions. Acta Ophthalmol (Copenh.) 2013;91(8):e641-5
   Google Scholar
• Ko JM, Fisher DE. A new era: melanoma genetics and therapeutics. J Pathol 2011;223(2):241-50
   PubMed Web of Science ®Google Scholar
• Sekulic A, Haluska P Jr, Miller AJ, et al. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc 2008;83(7):825-46
   PubMed Web of Science ®Google Scholar
• Pópulo H, Soares P, Rocha AS, et al. Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res 2010;20(2):107-17
   PubMed Web of Science ®Google Scholar
• Dratviman-Storobinsky O, Cohen Y, Frenkel S, et al. Lack of oncogenic GNAQ mutations in melanocytic lesions of the conjunctiva as compared to uveal melanoma. Invest Ophthalmol Vis Sci 2010;51(12):6180-2
   Google Scholar